Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Alumis Inc. ( (ALMS) ).
On May 21, 2025, Alumis Inc. completed its merger with ACELYRIN, Inc., creating a leading clinical-stage biopharma company with a strong portfolio of therapies and a robust financial position. The merger enhances Alumis’ ability to advance its clinical pipeline and extend its cash runway into 2027, supporting its mission to develop transformative therapies for patients. Additionally, Lynn Tetrault was appointed to the Alumis board of directors, while Henry Gosebruch will not join due to his new role as CEO of Galapagos.
The most recent analyst rating on (ALMS) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Alumis Inc. stock, see the ALMS Stock Forecast page.
Spark’s Take on ALMS Stock
According to Spark, TipRanks’ AI Analyst, ALMS is a Neutral.
Alumis Inc. presents a challenging investment case primarily due to its poor financial performance, characterized by zero revenue, increasing losses, and negative cash flows. The technical analysis also indicates bearish trends, further weighing on the stock’s performance. Valuation metrics are unfavorable with a negative P/E ratio and no dividend yield. However, the upcoming merger with ACELYRIN, Inc. offers a potential positive shift in the company’s prospects, providing financial stability and growth through an enhanced pipeline and financial resources.
To see Spark’s full report on ALMS stock, click here.
More about Alumis Inc.
Alumis Inc. is a late-stage biopharmaceutical company focused on developing next-generation targeted therapies for immune-mediated diseases. Utilizing a proprietary data analytics platform, Alumis is advancing a pipeline that includes oral tyrosine kinase 2 inhibitors for conditions like plaque psoriasis and systemic lupus erythematosus, as well as therapies for neuroinflammatory diseases and thyroid eye disease.
Average Trading Volume: 784,565
Technical Sentiment Signal: Strong Sell
Current Market Cap: $323.7M
For an in-depth examination of ALMS stock, go to TipRanks’ Stock Analysis page.